论文部分内容阅读
The tumor suppressor CYLD contains three cytoskeleton-associated protein glycine-rich (CAP-Gly) domains in the amino terminus and a deubiquitinase domain in the carboxyl terminus.The first two CAP-Gly domains mediate the interaction of CYLD with the microtubule cytoskeleton, whereas the deubiquitinase domain catalyzes the removal of lysine-63-1inked polyubiquitin chains from target proteins, leading to the inhibition of cell survival and proliferation.